Ratings Bumrungrad Hospital

Equities

BH

TH0168A10Z01

End-of-day quote Thailand S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
248 ^THB	-1.98%		+10.71%	+11.71%

04-25	Bumrungrad Hospital Public Company Limited Approves Dividend for an Operating Period from 1 July 2023 to 31 December 2023, Payable on 10 May 2024	CI
04-25	Bumrungrad Hospital Public Company Limited Elects Chanida Sophonpanich as Non-Executive Director	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.37 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BUMRUNGRAD HOSPITAL	+11.71%	5.32B		B
CVS HEALTH CORPORATION	-14.92%	84.68B		B-
HCA HEALTHCARE, INC.	+13.30%	81.12B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.62%	29.59B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B		B
FRESENIUS SE & CO. KGAA	-2.46%	16.36B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B		A-
PURE HEALTH HOLDING	-31.58%	11.77B	-	-
FRESENIUS MEDICAL CARE AG	-0.32%	11.72B		A-
DAVITA INC.	+27.44%	11.71B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes